Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Treasury Shares (2020 - 2025)

Historic Treasury Shares for 10x Genomics (TXG) over the last 6 years, with Q4 2025 value amounting to $7.8 million.

  • 10x Genomics' Treasury Shares rose 2053.4% to $7.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.8 million, marking a year-over-year increase of 2053.4%. This contributed to the annual value of $7.8 million for FY2025, which is 2053.4% up from last year.
  • Latest data reveals that 10x Genomics reported Treasury Shares of $7.8 million as of Q4 2025, which was up 2053.4% from $8.5 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Treasury Shares ranged from a high of $9.2 million in Q2 2025 and a low of $985386.0 during Q1 2021
  • Moreover, its 5-year median value for Treasury Shares was $5.8 million (2022), whereas its average is $5.1 million.
  • In the last 5 years, 10x Genomics' Treasury Shares soared by 159153.36% in 2021 and then plummeted by 860.25% in 2023.
  • Over the past 5 years, 10x Genomics' Treasury Shares (Quarter) stood at $1.3 million in 2021, then soared by 349.55% to $5.8 million in 2022, then dropped by 8.6% to $5.3 million in 2023, then rose by 21.73% to $6.5 million in 2024, then grew by 20.53% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q4 2025, $8.5 million for Q3 2025, and $9.2 million during Q2 2025.